Calendar of Events Donate Now
Subscribe for Email Updates

    Can Do MS provides what I would call ‘ideal care in an ideal setting’ for both people living with MS and those dedicated to helping them. Nowhere else will you find interdisciplinary professionals working so collaboratively in such a supportive setting.

    Programs Consultant
    •  


    Teva Neuroscience Investigates Potential Drug Laquinimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

    Posted Wednesday, October 8, 2008

    This information is provided for research purposes only and does not constitute an endorsement by The Heuga Center. The brands listed are registered trademarks of their respective owners.

    Do you want a treatment that is effective, easy to take and minimizes side effects? So do we. Join us in researching laquinimod, an investigational oral drug for MS.

    As you may know, all six currently available treatments for relapsing-remitting multiple sclerosis (RRMS) require injections or infusions. While numerous studies have demonstrated these drugs are effective at decreasing the rate and severity of relapses, many are associated with negative side effects, such as flu-like symptoms, which can make living with RRMS that much harder.

    Recognizing these challenges, Teva Neuroscience is now investigating a potential oral treatment option, laquinimod. Laquinimod is a pill, taken once-a-day, which has been given to more than 480 subjects in clinical trials. Results of a Phase II study of oral laquinimod recently published in the June 21, 2008 edition of The Lancet further demonstrated the experimental drug’s efficacy and tolerability.1 While the mechanism of action is still being confirmed, laquinimod is being tested to treat RRMS in a unique way – changing the means by which the immune system works rather than generally suppressing it.

    If you have confirmed RRMS, are between the ages of 18 and 55, have never been treated with interferon medications (Avonex®, Betaseron® or Rebif®) and have had at least one relapse in the last 12 months (or two relapses in the last 24 months), the Bravo study may be right for you.

    For more information, and to see if you may be eligible for the trial, please visit our Web site at www.tevaclinicaltrials.com or call us at 1-800-840-5601.

    We look forward to hearing from you.

    1Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085–92. 


    Back to press release list
    100 W. Beaver Creek Blvd. Suite 200 PO Box 5860 Avon, CO 81620 Phone: 970-926-1290 or 800-367-3101 Fax: 970-926-1295 Email: info@mscando.org
    MS Coalition Charity Navigator Consortium of Multiple Sclerosis Centers Independent Charities of America Humane Charity

    Can Do Multiple Sclerosis™ is a 501 (c)(3) nonprofit organization.
    Charitable Organization Number: 74-2337853

    Formerly The Heuga Center for Multiple Sclerosis | Founded by Jimmie Heuga

    A national nonprofit organization, Can Do MS is a leading provider of innovative lifestyle empowerment programs
    that empower people with MS and their support partners to transform and improve their quality of life.

    Donate to Can Do MS on December 9th for Colorado Gives Day and watch your donation go further! - Read More